Showing 671-680 of 2293 results for "".
- Prognostic Value of Serum NfL for Predicting Lesion Formation in MS Affirmed by ASCLEPIOS I/IIhttps://practicalneurology.com/news/prognostic-value-of-serum-nfl-for-predicting-lesion-formation-in-ms-affirmed-by-asclepios-iii/2470447/People with relapsing multiple sclerosis (RMS) who had higher 3- and 12-month on-treatment serum neurofilament light chain (sNfL) levels were found to have higher annualized rates of new or emerging T2 (neT2) lesion formation, according to findings from the phase 3 ASCLEPIOS I/II clinical trials
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Data from Danish MS Registry Study Provide Patterns and Predictors for Conversion from RRMS to SPMShttps://practicalneurology.com/news/data-from-danish-ms-registry-study-provide-patterns-and-predictors-for-conversion-from-rrms-to-spms/2470309/Researchers analyzing data from the Danish Multiple Sclerosis Registry revealed patterns and predictors for conversion from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SMPS). In all, 21.8% of people with relapsing-remitting multiple sclerosis (RRMS)
- Five-Year Data from ALITHIOS Study on MS Disability Presented at AAN 2023https://practicalneurology.com/news/five-year-data-from-alithios-study-on-ms-disability-presented-at-aan-2023/2470163/According to long-term results of a study presented at the Americ
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- FDA Removes Category C Warning of Possible Risk in Pregnancy and Breast Feeding for MS Treatment Interferon Beta-1ahttps://practicalneurology.com/news/fda-removes-category-c-warning-of-possible-risk-in-pregnancy-and-breast-feeding-for-ms-treatment-interferon-beta-1a/2469280/The Food and Drug Administration (FDA) has removed the category C warning from the package insert for interferon beta-1a (Rebif; EMD Serono, Rockland, MA). The change is based on the revised Pregnancy and Lactation Labeling Rule (PLLR) and new safety data that the FDA also approved for inclu
- High-Dose Biotin Did Not Improve Disability for Individuals With Active Secondary Progressive MS in Phase 3 Trialhttps://practicalneurology.com/news/high-dose-biotin-did-not-improve-disability-for-individuals-with-active-secondary-progressive-ms-in-phase-3-trial/2469189/The second pivotal phase 3 trial (SPI2) (NCT02936037) of investigational high-dose biotin (MD1003, MedDay Pharmaceuticals, Boston, MA) did not improve disability for individuals with active secondary p
- FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MShttps://practicalneurology.com/news/fda-approves-cladribine-tabletsfirst-and-only-short-course-treatment-for-relapsing-remitting-ms/2468787/The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Cladribine has a dosing schedule tha
- Women with Multiple Sclerosis May Be Missing Breast Cancer Screeningshttps://practicalneurology.com/news/women-with-multiple-sclerosis-may-be-missing-breast-cancer-screenings/2469895/In a study published in Neurology, women with multiple sclerosis (MS) were less likely to have breast cancer detected through screenings than women without MS. Women with MS were also more likely to have colorectal cancers detected early with screenings compared with women without MS. Th
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an